Case fatality rate of cancer patients with COVID-19 in a New York hospital system
COVID-19 in patients with cancer is associated with a significantly increased risk of case
fatality, suggesting the need for proactive strategies to reduce likelihood of infection and …
fatality, suggesting the need for proactive strategies to reduce likelihood of infection and …
[HTML][HTML] Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell …
…, A Shastri, M Janakiram, M Goldfinger… - Journal of hematology & …, 2020 - Springer
Axicabtagene ciloleucel (Axi-cel) is a CD-19 Chimeric Antigen Receptor T cell therapy
approved for the treatment of relapsed/refractory diffuse large B cell lymphoma. We treated ten …
approved for the treatment of relapsed/refractory diffuse large B cell lymphoma. We treated ten …
[PDF][PDF] Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer
…, GS Choudhary, M McCort, RA Sica, M Goldfinger… - Cancer Cell, 2022 - cell.com
We and others have shown the significant impact of COVID-19 infection among patients
with a cancer diagnosis, with increased morbidity and mortality with advanced age, co-…
with a cancer diagnosis, with increased morbidity and mortality with advanced age, co-…
Obesity and age at diagnosis of endometrial cancer
OBJECTIVE: Obesity is an established risk factor for development of endometrial cancer.
We hypothesized that obesity might also be associated with an earlier age at endometrial …
We hypothesized that obesity might also be associated with an earlier age at endometrial …
Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens
…, CF Connelly, JA Vergilio, M Goldfinger… - Blood, The Journal …, 2018 - ashpublications.org
Clonal hematopoiesis of indeterminate potential (CHIP) describes an expansion of
hematopoietic stem cells that harbor somatic mutations1-5 without an underlying hematologic …
hematopoietic stem cells that harbor somatic mutations1-5 without an underlying hematologic …
Delayed clearance of SARS-CoV2 in male compared to female patients: high ACE2 expression in testes suggests possible existence of gender-specific viral …
…, S Agrawal, N Chaterjee, K Pradhan, M Goldfinger… - MedRxiv, 2020 - medrxiv.org
The novel coronavirus SARS-CoV2 has been observed to cause a higher incidence and
greater severity of disease in males, as seen in multiple cohorts across the globe. The reasons …
greater severity of disease in males, as seen in multiple cohorts across the globe. The reasons …
Clinical trials assessing hypomethylating agents combined with other therapies: causes for failure and potential solutions
Purpose: Azacitidine and decitabine are hypomethylating agents (HMA), that is, both inhibit
and deplete DNA methyltransferase 1 (DNMT1). HMAs are standard single-agent therapies …
and deplete DNA methyltransferase 1 (DNMT1). HMAs are standard single-agent therapies …
[HTML][HTML] Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real …
…, A Shastri, K Gritsman, M Goldfinger… - … Hematology & Oncology, 2021 - Springer
Anti-CD19 chimeric antigen receptor T-cell therapies have shown striking clinical activity in
diffuse large B-cell lymphoma but robust biomarkers predictive of responsiveness are still …
diffuse large B-cell lymphoma but robust biomarkers predictive of responsiveness are still …
[HTML][HTML] Patterns of leukocyte recovery predict infectious complications after CD19 CAR-T cell therapy in a real-world setting
…, R Bartash, Y Puius, M McCort, M Goldfinger… - Stem cell …, 2021 - ncbi.nlm.nih.gov
Background Adoptive immunotherapy using CD19-targeted Chimeric antigen receptor T
cells (CAR-T) has revolutionized the treatment of relapsed/refractory diffuse large B-cell …
cells (CAR-T) has revolutionized the treatment of relapsed/refractory diffuse large B-cell …
Refractory DLBCL: challenges and treatment
M Goldfinger, DL Cooper - Clinical Lymphoma Myeloma and Leukemia, 2022 - Elsevier
Despite a greater understanding of pathologic factors that increase the chance for treatment
failure, initial therapy of diffuse large B cell lymphoma (DLBCL) has not evolved from R/…
failure, initial therapy of diffuse large B cell lymphoma (DLBCL) has not evolved from R/…